Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the ...
Wed, 08 Sep 2010 04:14:03 -0700
SAN FRANCISCO and ILLKIRCH, France, Sept. 8 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that ...
Read More...
